| Dictionary, Encyclopedia and Thesaurus - The Free Dictionary 1,733,249,356 visitors served. |
|
Dictionary/ thesaurus | Medical dictionary | Legal dictionary | Financial dictionary | Acronyms | Idioms | Encyclopedia | Wikipedia encyclopedia | ? |
eptifibatide |
Also found in: Wikipedia | 0.01 sec. |
|
eptifibatide /ep·ti·fib·a·tide/ (ep″tĭ-fib´ah-tīd) an inhibitor of platelet aggregation used for the prevention of thrombosis in patients with acute coronary syndrome or undergoing certain percutaneous coronary procedures. eptifibatide, an antiplatelet agent. indications It is used to treat acute coronary syndrome, including patients with percutaneous coronary intervention. contraindications The following factors prohibit its use: known hypersensitivity to this drug, active internal bleeding, history of bleeding, stroke within 1 month, major surgery with severe trauma, severe hypotension, history of intracranial bleeding, intracranial neoplasm, arteriovenous malformation/aneurysm, aortic dissection, and dependence on renal dialysis. adverse effects Life-threatening effects of this drug are stroke and bleeding. Hypotension is another serious adverse reaction. eptifibatide Integrilin Pharmacologic class: Platelet aggregation inhibitor Therapeutic class: Antiplatelet agent Pregnancy risk category B ActionDecreases platelet aggregation by binding to platelet-receptor glycoprotein, preventing binding of fibrinogen to platelets, which causes thrombus formation AvailabilityInjection: 10-ml vial (2 mg/ml), 100-ml vial (0.75 mg/ml) ⊘Indications and dosages ➣ Acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) Adults: 180 mcg/kg I.V. bolus (to maximum of 22.6 mg) over 1 to 2 minutes, followed by a continuous infusion of 2 mcg/kg/minute (to a maximum of 15 mg/hour) for up to 72 hours ➣ Prevention of thrombosis related to percutaneous coronary intervention (PCI) Adults: 180 mcg/kg (to a maximum of 22.6 mg) I.V. bolus immediately before PCI, then a continuous infusion of 2 mcg/kg/minute (to a maximum of 15 mg/hour), followed by a second 180-mcg/kg bolus 10 minutes after first bolus. Continue infusion until discharge or for up to 24 hours. Dosage adjustment• Renal impairment Contraindications• Hypersensitivity to drug or its components PrecautionsUse cautiously in: Administration• Withdraw single bolus dose from 10-ml vial into syringe, and give by I.V. push over 1 to 2 minutes. Follow single I.V. bolus dose with continuous I.V. infusion given undiluted from 100-ml vial spiked with infusion set connected to infusion control device.
Adverse reactionsCNS: headache, dizziness, asthenia, syncope CV: hypotension GI: nausea, diarrhea, constipation GU: hematuria Hematologic: bleeding tendency, thrombocytopenia Skin: flushing Other: bleeding at femoral access site InteractionsDrug-drug. Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral anticoagulants, thrombolytics, ticlopidine: increased risk of bleeding Other platelet aggregation inhibitors: serious bleeding Drug-diagnostic tests. Platelets: decreased count Drug-herbs. Most commonly used herbs: increased anticoagulant effect of eptifibatide Patient monitoring• Monitor vital signs and assess cardiovascular status, especially for syncope and hypotension. Patient teaching• Tell patient drug may cause serious adverse effects but can help prevent a heart attack. Reassure him that he'll be closely monitored during therapy. eptifibatide Integrilin® Cardiology An antithrombotic GP IIb/IIIa receptor antagonist that blocks fibrinogen and von Willebrand factor from binding to the surface of activated platelets How to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit webmaster's page for free fun content. |
|
| ? Mentioned in | ? References in periodicals archive | ||
|---|---|---|---|
| where he helped lead the successful launch of eptifibatide (Integrilin(R))), B. He has led the clinical development programs of t-PA, abciximab (ReoPro), eptifibatide (Integrilin), bivalirudin (Angiomax) and clopidogrel (Plavix). These results clearly show that treating patients with eptifibatide during coronary stent angioplasty procedures provides a sustainable, long-term benefit," stated James E. |
| Medical Dictionary |
| Free Tools: |
For surfers:
Free toolbar & extensions |
Word of the Day |
Help
For webmasters: Free content | Linking | Lookup box | Double-click lookup | Partner with us |
|---|